Kominers, S. D., Pathak, P. A., Sönmez, T., & Ünver, M. U. (2020). Paying It Backward and Forward: Expanding Access to Convalescent Plasma Therapy Through Market Design (Working Paper No. 27143; Working Paper Series). National Bureau of Economic Research. https://doi.org/10.3386/w27143

Horby, P., Mafham, M., Linsell, L., Bell, J. L., Staplin, N., Emberson, J. R., Wiselka, M., Ustianowski, A., Elmahi, E., Prudon, B., Whitehouse, A., Felton, T., Williams, J., Faccenda, J., Underwood, J., Baillie, J. K., Chappell, L., Faust, S. N., Jaki, T., … Landray, M. J. (2020). Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. MedRxiv, 2020.07.15.20151852. https://doi.org/10.1101/2020.07.15.20151852

CNN, J. G., Naomi Thomas, Dana Vigue and Jacqueline Howard. (n.d.). Oxford’s Covid-19 vaccine appears safe and induces immune response, early results suggest. CNN. Retrieved August 2, 2020, from https://www.cnn.com/2020/07/20/health/oxford-covid-19-vaccine-results-cansino-pfizer-study/index.html

Vaughan, A. (n.d.). Which covid-19 treatments work and how close are we to getting more? New Scientist. Retrieved 31 July 2020, from https://www.newscientist.com/article/2250176-which-covid-19-treatments-work-and-how-close-are-we-to-getting-more/

Vaughan, A. (n.d.). Coronavirus vaccine hope rises after a flurry of positive results. New Scientist. Retrieved July 29, 2020, from https://www.newscientist.com/article/2250084-coronavirus-vaccine-hope-rises-after-a-flurry-of-positive-results/

Sehgal, D. (2020). Analysis of Vaccines to tackle COVID-19 with Patent Review [Preprint]. SocArXiv. https://doi.org/10.31235/osf.io/q96wj

Herper, M. (2020, July 1). Covid-19 vaccine from Pfizer and BioNTech shows positive results. CNBC. https://www.cnbc.com/2020/07/01/coronavirus-vaccine-from-pfizer-and-biontech-shows-positive-results-report-says.html

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S. P., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fonter-Garfias, C., Shi, P.-Y., Tuereci, O., Tompkins, K. R., Walsh, E. E., … Jansen, K. U. (2020). Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. MedRxiv, 2020.06.30.20142570. https://doi.org/10.1101/2020.06.30.20142570

A COVID-19 vaccine has passed its first human trial. But is it the frontrunner? (2020, May 29). Science. https://www.nationalgeographic.com/science/2020/05/coronavirus-vaccine-passes-first-human-trial-but-is-it-frontrunner-cvd/

Lang, T. (2020). Plug COVID-19 research gaps in detection, prevention and care. Nature, 583(7816), 333–333. https://doi.org/10.1038/d41586-020-02004-1

Mallapaty, S. (2020). The mathematical strategy that could transform coronavirus testing. Nature. https://doi.org/10.1038/d41586-020-02053-6

Richards, A. D. (2020). Ethical Guidelines for Deliberately Infecting Volunteers with COVID-19 [Preprint]. SocArXiv. https://doi.org/10.31235/osf.io/jb7gq

Rosendaal, F. R. (2020). Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949. International Journal of Antimicrobial Agents, 106063. https://doi.org/10.1016/j.ijantimicag.2020.106063

Ecker, U. K. H., Butler, L. H., Cook, J., Hurlstone, M. J., Kurz, T., & Lewandowsky, S. (2020). Using the COVID-19 economic crisis to frame climate change as a secondary issue reduces mitigation support. Journal of Environmental Psychology, 101464. https://doi.org/10.1016/j.jenvp.2020.101464

Haushofer, J., & Metcalf, C. J. E. (2020). Which interventions work best in a pandemic? Science. https://doi.org/10.1126/science.abb6144

Jena, A. B., & Worsham, C. M. (2020, June 30). What Coronavirus Researchers Can Learn From Economists. The New York Times. https://www.nytimes.com/2020/06/30/upshot/coronavirus-economists-dexamethasone.html

Gorey, C. (2020, June 29). RCSI team to start trial for promising Covid-19 therapy for severe infections. Silicon Republic. https://www.siliconrepublic.com/innovation/rcsi-trial-covid-19-therapy-alpha-1-antitrypsin

Meyer, B., Torriani, G., Yerly, S., Mazza, L., Calame, A., Arm-Vernez, I., Zimmer, G., Agoritsas, T., Stirnemann, J., Spechbach, H., Guessous, I., Stringhini, S., Pugin, J., Roux-Lombard, P., Fontao, L., Siegrist, C.-A., Eckerle, I., Vuilleumier, N., & Kaiser, L. (2020). Validation of a commercially available SARS-CoV-2 serological immunoassay. Clinical Microbiology and Infection, 0(0). https://doi.org/10.1016/j.cmi.2020.06.024

Data show panic, disorganization dominate the study of Covid-19 drugs. (2020, July 6). STAT. https://www.statnews.com/2020/07/06/data-show-panic-and-disorganization-dominate-the-study-of-covid-19-drugs/

KupferschmidtJul. 2, K., 2020, & Pm, 5:30. (2020, July 2). One U.K. trial is transforming COVID-19 treatment. Why haven’t others delivered more results? Science | AAAS. https://www.sciencemag.org/news/2020/07/one-uk-trial-transforming-covid-19-treatment-why-haven-t-others-delivered-more-results

Corbett, K. S., Edwards, D., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., … Graham, B. S. (2020). SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness. BioRxiv, 2020.06.11.145920. https://doi.org/10.1101/2020.06.11.145920

Zhou, Q., Chen, V., Shannon, C. P., Wei, X.-S., Xiang, X., Wang, X., Wang, Z.-H., Tebbutt, S. J., Kollmann, T. R., & Fish, E. N. (2020). Interferon-α2b Treatment for COVID-19. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.01061

Chen, L., Zhang, Z., Fu, J., Feng, Z., Zhang, S.-Z., Han, Q.-Y., Zhang, X., Xiao, X., Chen, H.-M., Liu, L.-L., Chen, X.-L., Lan, Y.-P., Zhong, D.-J., Hu, L., Wang, J.-H., Yu, X.-H., She, D.-Y., Zhu, Y.-H., & Yin, Z.-Y. (2020). Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: A prospective open-label randomized controlled study. MedRxiv, 2020.06.19.20136093. https://doi.org/10.1101/2020.06.19.20136093

Sbidian, E., Josse, J., Lemaitre, G., Mayer, I., Bernaux, M., Gramfort, A., Lapidus, N., Paris, N., Neuraz, A., Lerner, I., Garcelon, N., Rance, B., Grisel, O., Moreau, T., Bellamine, A., Wolkenstein, P., Varoquaux, G., Caumes, E., Lavielle, M., … Audureau, E. (2020). Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: A cohort study of 4,642 in-patients in France. MedRxiv, 2020.06.16.20132597. https://doi.org/10.1101/2020.06.16.20132597

Emanuel, E. J., & Offit, P. A. (2020, June 8). Opinion | Could Trump Turn a Vaccine Into a Campaign Stunt? The New York Times. https://www.nytimes.com/2020/06/08/opinion/trump-coronavirus-vaccine.html

Thorp, H. H. (2020). Underpromise, overdeliver. Science, 367(6485), 1405–1405. https://doi.org/10.1126/science.abb8492

Rheumatology, T. L. (2020). COVID-19: A time to reflect. The Lancet Rheumatology, 2(6), e309. https://doi.org/10.1016/S2665-9913(20)30102-8

Boseley, Sarah, and Melissa Davey. ‘Covid-19: Lancet Retracts Paper That Halted Hydroxychloroquine Trials’. The Guardian, 4 June 2020, sec. World news. https://www.theguardian.com/world/2020/jun/04/covid-19-lancet-retracts-paper-that-halted-hydroxychloroquine-trials.

Bail, C. A. (2016). Combining natural language processing and network analysis to examine how advocacy organizations stimulate conversation on social media. Proceedings of the National Academy of Sciences, 113(42), 11823–11828. https://doi.org/10.1073/pnas.1607151113

Kurzweil, R. (2020 May 19). AI-Powered Biotech Can Help Deploy a Vaccine In Record Time. Wired. https://www.wired.com/story/opinion-ai-powered-biotech-can-help-deploy-a-vaccine-in-record-time/

The First Shot: Inside the Covid Vaccine Fast Track. (n.d.). Wired. Retrieved May 30, 2020, from https://www.wired.com/story/moderna-covid-19-vaccine-trials/

UKCDR - COVID-19 Research Project Tracker

Coronavirus vaccine safe in early trial, hydroxychloroquine may increase death risk. (2020, May 23). Reuters. https://www.reuters.com/article/us-health-coronavirus-science-idUSKBN22Y2OD

Wagenmakers, E., & Gronau, Q. F. (2020, April 27). Efficacy of Hydroxychloroquine in Patients with COVID-19 (Chen et al., 2020): Moderate Evidence for a Treatment Effect on Pneumonia. Retrieved from psyarxiv.com/7nk8z

Mullard, A. (2020). Flooded by the torrent: The COVID-19 drug pipeline. The Lancet, 395(10232), 1245–1246. https://doi.org/10.1016/S0140-6736(20)30894-1

The individual change in REE to a given change in dose varied radically. The dose change was only 50 mcg, which seemed to change TSH about half what they've calculated for 15% REE change. That is to say, it looks like a 50 mcg dose reduction will only raise TSH from 1.0 to 5.0, not to 10.0. This is my personal guesstimate, and will need to be properly calculated from other studies. My point is merely that 50 mcg will not cause the full 15% REE increase. Additionally, the response to 50 mcg may depend on initial TSH.

It looks like TSH changes that remained hyperthyroid (i.e. bellow 1.0) had little effect on REE. This might be because the body is maintaining thyroid status, or that REE is more like an on/off switch. However, this only covers relatively small changes in thyroxine dose.

It is unclear how supraphysiological doses effect REE. It seems likely that the ten times greater dose (500 mcg) used for depression would significantly increase REE.

Note that this was a two week study. It's hard to guess whether greater benefit would occur over longer periods.

This is consistent with the open label data. The dose is also similar. Combining this placebo-controlled trial with the three open-label supraphysiological thyroxine studies that I've seen, that is sufficient for me to conclude efficacy. Namely, combining with Pfeiffer et al (350 mcg), Rudas et al (235 mcg) and Bauer et al (482 mcg)

I would like to see if this study mentions nonresponders. Those three other studies found roughly a 50% response rate. Thus, the effect size in responders may be twice as significant.

Thus, a 15% expected increase would be reasonable for a euthyroid subject such as myself. However, since T3 reduces weight compared to T4, it is possible the weight loss indicates greater energy expenditure.

Interesting that the diet group worked better. I'd like to see if it's statistically significantly better than the drug group. It's also worth asking whether sodium was the only important dietary change, or if avoiding sodium caused many other dietary improvements.

Fascinating. Neck circumference suggests that sodium intake may indeed be the significant dietary factor. The recommended diet wasn't even very restricted in sodium.

Is there anything it can't do? I have noted, however, that larger doses cause nausea for me. That is, 3 or more grams on an empty stomach. I just vomited after taking 7.5 grams before my meal, but I have not yet established the causal link. It is the largest amount I've ever taken at one time. I suspect that it may have contributed significantly, but that it was also one out of half a dozen factors.

This is the only group with a TSH significantly below the reference range. The reason, of course, is that the patients with the most symptoms ended up getting the highest doses of thyroxine (T4) by the end of the study.

I am checking

Starts with a small amount of history and its use; this article actually discusses an experimental seminar done to test the usefulness of Slack in education. (4/5)

NOTE: MOOC is a Massive Online Open Course)

https://www.trustarts.org/pct_home/visit/facilities/oreilly-theater

Much insight in this phrase.